AGM Statement

Cambridge Antibody Tech Group PLC
07 February 2003

02/CAT/06

Page 1 of 3

FOR IMMEDIATE RELEASE
15.30 GMT 10.30 EST Friday 7 February 2003


For Further Information Contact:
Cambridge Antibody Technology                       Weber Shandwick Square Mile (Europe)
                                                    Tel: [phone]
Tel: [phone]                           Kevin Smith
Peter Chambre, Chief Executive Officer              Graham Herring
John Aston, Chief Finanancial Officer
Rowena Gardner, Director of Corporate
Communications
                                                    BMC Communications/The Trout Group (USA)
                                                    Tel: [phone]
                                                    Brad Miles, ext. 17 (media)
                                                    Brandon Lewis, ext. 15 (investors)


CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
REPORTS OUTCOME OF ANNUAL GENERAL MEETING

Cambridge, UK... Cambridge Antibody Technology  (LSE: CAT, NASDAQ: CATG)
reports that at its Annual General Meeting, held at 12:30 GMT on Friday 7
February 2003, all resolutions were duly passed.

                                        -ENDS-


Notes to Editors:

Cambridge Antibody Technology (CAT)

• CAT is a UK-based biotechnology company using its proprietary
technologies and capabilities in human monoclonal antibodies for drug discovery
and drug development.  Based near Cambridge, England, CAT currently employs
around 290 people.

• CAT is a leader in the discovery and development of human therapeutic
antibodies and has an advanced proprietary platform technology for rapidly
isolating human monoclonal antibodies using phage display systems. CAT has
extensive phage antibody libraries, currently incorporating more than 100
billion distinct antibodies. These libraries form the basis for the Company's 
strategy to develop a portfolio of antibody-based drugs.

• HumiraTM, the leading CAT-derived antibody, isolated and optimised in
collaboration with Abbott, has been approved by the US Food and Drug
Administration for marketing in the US as a treatment for rheumatoid arthritis.
Six further CAT-derived human therapeutic antibodies are at various stages of
clinical trials.

• CAT has alliances with a large number of pharmaceutical and
biotechnology companies to discover, develop and commercialise human monoclonal
antibody-based products. CAT has also licensed its proprietary human phage
antibody libraries to several companies for target validation and drug
discovery. CAT's collaborators include: Abbott, Amgen, Amrad, Chugai,
Elan, Genzyme, Human Genome Sciences, Merck & Co, Pharmacia and Wyeth Research.

• CAT is listed on the London Stock Exchange and on NASDAQ since June
2001. CAT raised £41m in its IPO in March 1997 and £93m in a secondary offering
in March 2000.





Application of the Safe Harbor of the US Private Securities Litigation Reform
Act of 1995: This press release contains statements about CAT that are forward
looking statements.  All statements other than statements of historical facts
included in this press release may be forward looking statements within the
meaning of Section 21E of the US Securities Exchange Act of 1934.

These forward looking statements are based on numerous assumptions regarding 
CAT's present and future business strategies and the environment in which
CAT will operate in the future.  Certain factors that could cause CAT's
actual results, performance or achievements to differ materially from those in
the forward looking statements include: market conditions, CAT's ability
to enter into and maintain collaborative arrangements, success of product
candidates in clinical trials, regulatory developments and competition.



                      This information is provided by RNS
            The company news service from the London Stock Exchange